# Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

Study · id `cardio:ct-nct03620890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03620890](<https://clinicaltrials.gov/study/NCT03620890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03620890

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT03620890. Randomized; no masking; primary purpose treatment. Start 2018-09-04 (actual); primary completion 2020-07-29 (actual). Results posted on 2021-08-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT03620890, source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)
- Started: 2018-09-04 (actual) (ClinicalTrials.gov record NCT03620890, source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)
- Primary completion: 2020-07-29 (actual) (ClinicalTrials.gov record NCT03620890, source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)
- Completion: 2020-07-29 (actual) (ClinicalTrials.gov record NCT03620890, source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)
- Results first posted: 2021-08-18 (ClinicalTrials.gov record NCT03620890, source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03620890, source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03620890-2021-09-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
- Acronym: Determin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Neutral Protamine Hagedorn (NPH)
- Intervention (Drug): Detemir insulin
- Lead sponsor: The University of Texas Health Science Center, Houston
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: The University of Texas Health Science Center, Houston (`cardio:org-the-university-of-texas-health-science-center-houston`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial (`cardio:pubmed-33865836`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: afa6b86c3dbf6b6b3bcea39013650f9e6a7ba0e841d4f70c3d81f232037aca1a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
